Habib Bank Limited Pharmaceutical Import Profile — Pakistan (DGFT 2022–2026)

Name: Habib Bank Limited Pharmaceutical Import Records from India — 3 Products, $1.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Habib Bank Limited — Pharmaceutical Importer Profile (2026) | 3 Products, $1.3M Trade | TransData Nexus

Habib Bank Limited

Pharmaceutical Importer · Pakistan · Advanced Oncology Focus · $1.3M Total Trade · DGFT Verified

Habib Bank Limited is a pharmaceutical importer based in Pakistan with a total trade value of $1.3M across 3 products in 2 therapeutic categories. Based on 28 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Habib Bank Limited sources from 13 verified Indian suppliers, with Cipla Limited accounting for 35.1% of imports.

Habib Bank Limited — Import Portfolio & Supplier Network

Habib Bank Limited import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Habib Bank Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$894.2K	49	35.1%
Bharat Serums And Vaccines Limited	$875.7K	28	34.4%
Naprod Life Sciences Private Limited

What Formulations Does Habib Bank Limited Import?

Formulation	Value	Ships
Snake venom antiserum	$150.0K	3
Imatib alpha 100 capsules ( imatinib capsules 100 MG )(1x10's x 60120 packs =601200 nos	$150.0K	3
Snake venom antiserum (lyophilized)	$122.4K	3
Equirab 1000 IU/5ML [ rabies antiserum	$100.0K	2
Equirab 1000 IU/5ML [ rabies antiserum	$84.8K	2
Soranib 200 MG tablet (sorafenib)inv.qty.5120 Pack 1x30's=153600	$65.8K	3
Orlistat pellets	$64.0K	2
Capecitabine tablets USP 500MG (12x10'stablets alu-alu-blister Pack) (as per invoice)	$60.7K	6
Equirab 1000 IU 5ML rabies antiserum	$50.0K	1
Pharmaceutical raw material[allopathic]o	$50.0K	1
Equirab 1000 IU/5ML [rabies antiserum	$50.0K	1
Imatib alpha 100 capsules ( imatinib capsules 100 MG )(1 x 10's x 23,580 Pack=235800 nos)	$50.0K	1
Imatib alpha 100 capsules ( imatinib capsules 100 MG )(1 x 10's x 23,390 Pack=233900 nos)	$50.0K	1
Imatib alpha 100 capsules ( imatinib capsules 100 MG )(1 x 10'sx61,710 Pack=617100 nos)	$50.0K	1
Snake venom antiserum (lyophilized) batch no. a18223057mfg. dt. 12. 2023exp dt.11.	$50.0K	1

Habib Bank Limited imports 94 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Imatinib	Advanced Oncology	$750.0K	15	2.6%	6
2	Serum	Other	$500.0K	10	1.8%	12
3	Sorafenib	Advanced Oncology	$65.8K	3	0.4%	6

Habib Bank Limited imports 3 pharmaceutical products across 2 categories into Pakistan totaling $1.3M.

Habib Bank Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Habib Bank Limited (HBL), established in 1941, is Pakistan's first commercial bank and a leading financial institution in the country. Headquartered in Karachi, HBL operates over 1,640 branches and 2,264 ATMs globally, serving more than 40 million clients. In 2004, the Aga Khan Fund for Economic Development (AKFED) acquired a 51% stake in HBL, gaining management control. By April 2015, the Government of Pakistan divested its remaining 41.5% shareholding, making HBL Pakistan's largest private bank.

While HBL is primarily a commercial bank, it has diversified its services to include trade financing and facilitating international transactions. This diversification has positioned HBL as a key player in Pakistan's pharmaceutical import sector, particularly in sourcing finished pharmaceutical formulations from India. The bank's extensive network and financial expertise enable it to manage complex import operations, ensuring the availability of essential medicines in Pakistan.

2Distribution Network

HBL's distribution network is extensive, with over 1,640 branches and 2,264 ATMs across Pakistan and international locations. This widespread presence facilitates efficient logistics and distribution of imported pharmaceutical products. The bank's robust financial infrastructure supports seamless transactions and supply chain management, ensuring timely delivery of medicines to various stakeholders within Pakistan's healthcare system.

3Industry Role

In Pakistan's pharmaceutical supply chain, HBL functions as a financial intermediary, facilitating the import of finished pharmaceutical formulations from India. By leveraging its banking and trade financing capabilities, HBL ensures the smooth procurement and distribution of essential medicines, thereby playing a crucial role in maintaining the country's pharmaceutical supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Habib Bank Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

HBL's pharmaceutical imports from India are concentrated in a few key suppliers, with CIPLA LIMITED and BHARAT SERUMS AND VACCINES LIMITED accounting for a combined total of $1.77 million, representing approximately 83% of the total import value. This concentration indicates a strategic choice to source from established and reliable suppliers, ensuring consistent quality and supply. The stability of these relationships is evidenced by the frequency and volume of shipments, suggesting a strong and dependable supply chain.

2Supply Chain Resilience

HBL's supply chain resilience is bolstered by its partnerships with multiple Indian suppliers, including CIPLA LIMITED and BHARAT SERUMS AND VACCINES LIMITED. This diversification mitigates risks associated with single-source dependency. The bank's established relationships with these suppliers, evidenced by numerous shipments, indicate a stable and reliable supply chain. Additionally, HBL's extensive distribution network within Pakistan ensures that imported pharmaceutical products reach their destinations efficiently, further enhancing supply chain resilience.

3Strategic Implications

Importing Pharmaceuticals into Pakistan — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Pakistan

1Regulatory Authority & Framework

The Drug Regulatory Authority of Pakistan (DRAP) is the primary regulatory body overseeing the import and distribution of pharmaceutical products in Pakistan. Established under the Drug Regulatory Authority of Pakistan Act, 2012, DRAP enforces the Drugs Act, 1976, and other relevant regulations to ensure the quality, safety, and efficacy of therapeutic goods. The Drugs (Labeling and Packaging) Rules, 1986, mandate that all imported packaged medicines display the name and prescription material in accordance with these regulations. (tipp.gov.pk)

2Import Licensing & GMP

To import pharmaceutical products into Pakistan, companies must obtain a Drug Import License (D.I.L.) from DRAP. The application process involves submitting necessary documents through DRAP's online portal, with a processing timeline of approximately five days. (dra.gov.pk) Additionally, imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards recognized by DRAP, ensuring that products meet quality and safety requirements.

3Quality & Labeling

Habib Bank Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

HBL's focus on importing finished pharmaceutical formulations, particularly in the advanced oncology category, aligns with the growing demand for cancer treatments in Pakistan. The substantial import value of Imatinib and Sorafenib indicates a strategic emphasis on providing essential oncology medications to meet the needs of patients. This product strategy reflects HBL's commitment to addressing critical healthcare requirements in the country.

2Sourcing Profile

HBL's sourcing strategy involves importing finished pharmaceutical formulations from established Indian suppliers, such as CIPLA LIMITED and BHARAT SERUMS AND VACCINES LIMITED. This approach ensures a consistent supply of high-quality products, particularly in the oncology therapeutic category. The bank's focus on finished formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a preference for ready-to-use products that can be directly distributed within Pakistan's healthcare system.

3Market Positioning

By importing a significant volume of oncology medications, HBL positions itself as a key supplier of essential cancer treatments in Pakistan. This market positioning serves a critical segment of the healthcare market, addressing the needs of patients requiring specialized and life-saving medications.

Seller's Guide — How to Become a Supplier to Habib Bank Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with HBL, especially in the oncology therapeutic category. The existing gaps in HBL's sourcing, such as the need for additional suppliers or alternative formulations, present avenues for new entrants to establish partnerships. Engaging with HBL could provide Indian exporters with a stable channel to distribute their products in Pakistan, leveraging HBL's established infrastructure and market presence.

2Requirements & Qualifications

Indian exporters seeking to supply pharmaceutical products to HBL and the Pakistan market must ensure that their products are registered with DRAP and comply with GMP standards recognized by the authority. Additionally, products must adhere to the labeling requirements set forth in the Drugs (Labeling and Packaging) Rules, 1986, ensuring that all imported packaged medicines display the name and prescription material in accordance with these regulations. (tipp.gov.pk)

3How to Approach

Frequently Asked Questions — Habib Bank Limited

What products does Habib Bank Limited import from India?

Habib Bank Limited imports 3 pharmaceutical products across 2 categories. Top imports: Imatinib ($750.0K), Serum ($500.0K), Sorafenib ($65.8K).

Who supplies pharmaceuticals to Habib Bank Limited from India?

Habib Bank Limited sources from 13 verified Indian suppliers. The primary supplier is Cipla Limited (35.1% of imports, $894.2K).

What is Habib Bank Limited's total pharmaceutical import value?

Habib Bank Limited's total pharmaceutical import value from India is $1.3M, based on 28 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Habib Bank Limited focus on?

Habib Bank Limited imports across 2 categories. The largest: Advanced Oncology (62.0%), Other (38.0%).

Get Full Habib Bank Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.